Garnet,
Thank you very much for taking the time to do this and sharing
your personal notes with us. I think this is an excellent analysis of
what was said.
Jayne
Please sign the petition to the UK Govt to fund trials for LDN
http://www.ldnnow.com/
From:
rheumatoidarthritis-lowdosenaltrexone@yahoogroups.com
[mailto:rheumatoidarthritis-lowdosenaltrexone@yahoogroups.com] On Behalf Of Garnet
Sent: 29 June 2009 19:56
To: LDN List; LDN_Users; LDN Support; LDN For CFS; LDN for Fibro;
LDN_4_Cancer; LDN RA
Subject: [rheumatoidarthritis-lowdosenaltrexone] My Notes on Dr Zagon's
Interview on Mary Boyle Bradley's Blog Talk Radio
This was an excellent and fast moving interview. I have
listened to it now seven or eight times to be clear on what
Dr Zagon was saying. It is an interview and I was not there
asking questions to clarify and be certain I understood what
he was saying so these notes are subject to error. I would
encourage everyone to listen to the interview and book mark
it for future reference.
Garnet
================================
My Notes from the show:
http://www.blogtalkradio.com/Mary-Boyle-Bradley/2009/06/23/The-Mary-Bradley-Show
The more correct term for the treatment we call Low Dose
Naltrexone is "Intermittent Opiate Blockade".
He pointed out that even low doses of Naltrexone if taken
too often will cause a long term or continuous blockade.
Some people have mistakenly taken more than one dose a day
and reported that their formerly beneficial results had
stopped.
It is the 4-6 hour short blockade that raises both the
number of opiate receptors and the level of endorphins in
the body. Endorphins result in Metenkephalin formation. The
actual compound that mediates the effect is Metenkephalin or
Opioid Growth Factor. OGF can be given once a week and have
the beneficial effect.
The number of opiate receptors an individual has, as well as
their level of endorphins, will influence how well LDN will
work. If the number of receptors or level of endorphins is
too low then LDN will not work. However metenkephlin or OGF
will work and has been used in treating cancer, because it
is providing the opioids that their body does not have. More
clinical studies are needed here.
He surprisingly said he did not feel that people should use
LDN cream because it persists for a long time. He did say he is
working with the cream form and is familiar with it.
What he seemed to be saying is that because the length
of blockade is known only with compounded
tablets that is the only form people should use. I believe
he seemed to be pointing to the use of LDN Liquid, although
he did not clearly state this and actually seemed to have
mispoken when he said that no one should use oral LDN, I
believe he meant liquid because he did further state after
that only compounded tablets should be used -- with known
fillers since some people have a problem with some fillers
being allergenic and some fillers prolonging release.
Evening dosing is a myth that he says he actually started
many years ago when someone asked about when to take it and
he casually said that evening might avoid experiencing some
of the side effects since you would tend to sleep through
them. He did not mean it would not work taken at other times
of the day.
Dr Zagon was emphatic about the myth that endorphins are
released on a circadian rythm is not true and LDN will work
when taken any time of day.
Some people need more or less than 4.5 mg and even may
benefit from every other or every third day dosing if LDN
seems to stop working at some point, some times 6 - 12
months after starting with initially positive results, due
to LDN building up in the system. Too much Naltrexone can
accelerate tumor growth. So the dose and period of blockade
is important particularly in cancer. In wound healing
accelerated growth would be a benefit. For the same reason
he does not reccomend it in liver disease since higher
levels of LDN could result due to the Liver not metabolizing
it as well in a diseased state.
Naltrexone was tested for only 12 weeks orginally. The
opiate receptor was not even discovered when Naltrexone was
approved. So much of these effects were not studied during
the Investigational phases of Naltrexone approval.